Honorary Fellow
Overview
Dr. Sherman Leung is the Head of Research Operations at Wesley Research Institute, which is the official research partner for UnitingCare encompassing the four UnitingCare hospitals in Queensland as well as Lifeline, Blue Care, and Family and Disability Services. He is a PhD trained scientist, conducting his research training under the leadership of Prof. Josephine Forbes at Mater Research - The University of Queensland.
His research is published in well regarded peer-reviewed journals, including recently in 'Diabetes', receiving the Cover Image, an 'In This Issue' feature, and shared across the Australian-wide 7 Network news. He has extensive experience in clinical trials, having worked at Microba Life Sciences, an ASX-listed biotechnology start-up, and Nucleus Network, Australia’s largest early phase clinical trial site having overseen the conduct of several high-profile COVID-19 projects including that of Nuvaxovid by Novavax that is now authorised for use by the TGA, EMEA & FDA across many jurisdictions worldwide.
At Wesley Research Institute, he is responsible for the Clinical Trials Centre, Biobank/s, Grants Office and Research Programs that span the clinical and applied health sciences. He has held numerous voluntary appointments including being a member of the Metro North Human Research Ethics Committee (HREC). He remains an active contributor to higher education facilitating lectures/workshops covering clinical research and ethics for Griffith University and The University of Queensland, as well as research placements for medical students as part of their MD program and postgraduate students enrolled in the 'Masters in Pharmaceutical Industry Practice' degree at The University of Queensland.
Publications
-
Journal Article: Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes
Leung, Sherman S., Lenchik, Nataliya, Mathews, Clayton, Pugliese, Alberto, McCarthy, Domenica A., Le Bagge, Selena, Ewing, Adam, Harris, Mark, Radford, Kristen J., Borg, Danielle J., Gerling, Ivan and Forbes, Josephine M. (2023). Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes. Scientific Reports, 13 (1) 12948, 1-15. doi: 10.1038/s41598-023-39243-x
-
Journal Article: Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells
Leung, Sherman S., Borg, Danielle J., McCarthy, Domenica A., Boursalian, Tamar E., Cracraft, Justen, Zhuang, Aowen, Fotheringham, Amelia K., Flemming, Nicole, Watkins, Thomas, Miles, John J., Groop, Per-Henrik, Scheijen, Jean L., Schalkwijk, Casper G., Steptoe, Raymond J., Radford, Kristen J., Knip, Mikael and Forbes, Josephine M. (2022). Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells. Diabetes, 71 (9), 1994-2008. doi: 10.2337/db22-0177
-
Journal Article: Short duration alagebrium chloride therapy prediabetes does not inhibit progression to autoimmune diabetes in an experimental model
Borg, Danielle J., Faridi, Pouya, Giam, Kai Lin, Reeves, Peta, Fotheringham, Amelia K., McCarthy, Domenica A., Leung, Sherman, Ward, Micheal S., Harcourt, Brooke E., Ayala, Rochelle, Scheijen, Jean L., Briskey, David, Dudek, Nadine L., Schalkwijk, Casper G., Steptoe, Raymond, Purcell, Anthony W. and Forbes, Josephine M. (2021). Short duration alagebrium chloride therapy prediabetes does not inhibit progression to autoimmune diabetes in an experimental model. Metabolites, 11 (7) 426, 1-21. doi: 10.3390/metabo11070426
Grants
-
(2016–2018) University of Miami
Supervision
-
The receptor for advanced glycation end products and its role in Type 1 diabetes development
Doctor Philosophy
Publications
Journal Article
-
Leung, Sherman S., Lenchik, Nataliya, Mathews, Clayton, Pugliese, Alberto, McCarthy, Domenica A., Le Bagge, Selena, Ewing, Adam, Harris, Mark, Radford, Kristen J., Borg, Danielle J., Gerling, Ivan and Forbes, Josephine M. (2023). Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes. Scientific Reports, 13 (1) 12948, 1-15. doi: 10.1038/s41598-023-39243-x
-
Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells
Leung, Sherman S., Borg, Danielle J., McCarthy, Domenica A., Boursalian, Tamar E., Cracraft, Justen, Zhuang, Aowen, Fotheringham, Amelia K., Flemming, Nicole, Watkins, Thomas, Miles, John J., Groop, Per-Henrik, Scheijen, Jean L., Schalkwijk, Casper G., Steptoe, Raymond J., Radford, Kristen J., Knip, Mikael and Forbes, Josephine M. (2022). Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells. Diabetes, 71 (9), 1994-2008. doi: 10.2337/db22-0177
-
Borg, Danielle J., Faridi, Pouya, Giam, Kai Lin, Reeves, Peta, Fotheringham, Amelia K., McCarthy, Domenica A., Leung, Sherman, Ward, Micheal S., Harcourt, Brooke E., Ayala, Rochelle, Scheijen, Jean L., Briskey, David, Dudek, Nadine L., Schalkwijk, Casper G., Steptoe, Raymond, Purcell, Anthony W. and Forbes, Josephine M. (2021). Short duration alagebrium chloride therapy prediabetes does not inhibit progression to autoimmune diabetes in an experimental model. Metabolites, 11 (7) 426, 1-21. doi: 10.3390/metabo11070426
-
Advanced glycation end products as predictors of renal function in youth with type 1 diabetes
Forbes, Josephine M., Le Bagge, Selena, Righi, Samuel, Fotheringham, Amelia K., Gallo, Linda A., McCarthy, Domenica A., Leung, Sherman, Baskerville, Tracey, Nisbett, Janelle, Morton, Adam, Teasdale, Stephanie, D'Silva, Neisha, Barrett, Helen, Jones, Timothy, Couper, Jennifer, Donaghue, Kim, Isbel, Nicole, Johnson, David W., Donnellan, Leigh, Deo, Permal, Akison, Lisa K., Moritz, Karen M. and O'Moore-Sullivan, Trisha (2021). Advanced glycation end products as predictors of renal function in youth with type 1 diabetes. Scientific Reports, 11 (1) 9422, 9422. doi: 10.1038/s41598-021-88786-4
-
Zhuang, Aowen, Yap, Felicia Y. T., Borg, Danielle J., McCarthy, Domenica, Fotheringham, Amelia, Leung, Sherman, Penfold, Sally A., Sourris, Karly C., Coughlan, Melinda T., Schulz, Benjamin L. and Forbes, Josephine M. (2021). The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition). Endocrinology, Diabetes and Metabolism, 4 (3) e00278, e00278. doi: 10.1002/edm2.278
-
Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes
Le Bagge, Selena, Fotheringham, Amelia K., Leung, Sherman S. and Forbes, Josephine M. (2020). Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes. Medicinal Research Reviews, 40 (4) med.21654, 1200-1219. doi: 10.1002/med.21654
-
Receptor for advanced glycation end products (RAGE) in type 1 diabetes pathogenesis
Leung, Sherman S., Forbes, Josephine M. and Borg, Danielle J. (2016). Receptor for advanced glycation end products (RAGE) in type 1 diabetes pathogenesis. Current Diabetes Reports, 16 (10) 100, 100. doi: 10.1007/s11892-016-0782-y
Conference Publication
-
Leung, S. S.-Y., Borg, D. J., McCarthy, D., Zhuang, A., Fotheringham, A., Di Trapani, G., Groop, P.-H., Knip, M. and Forbes, J. (2015). Human soluble receptor for advanced glycation end products therapy reduces autoimmune diabetes in the non-obese diabetic mouse. Joint Annual Conference of the International Society for Pediatric and Adolescent Diabetes and Australasian Paediatric Endocrine Group (ISPAD+APEG 2015), Brisbane, QLD Australia, 7-10 October 2015. Hoboken, NJ USA: Wiley-Blackwell Publishing. doi: 10.1111/pedi.12309
-
Leung, Sherman S., Borg, Danielle J., Paul, Moumita, Sharland, Alexandra F. and Forbes, Josephine M. (2015). Gene Therapy Using Recombinant Adeno-Associated Virus Serotype 2/8 Liver-Directed Expression of Srage in Experimental Type 1 Diabetes. 9th Biennial Meeting of the Australasian-Gene-and-Cell-Therapy-Society (AGCTS), Parkville, VIC Australia, 29 April - 1 May 2015. Hoboken, NJ United States: Wiley-Blackwell.
-
Leung, Sherman, Borg, Danielle J., McCarthy, Domenica, Zhuang, Aowen, Forbes, Josephine and Ward, Micheal (2015). Recombinant human soluble receptor for advanced glycation end product therapy reduces autoimmune diabetes in the NOD mouse model. 75th Scientific Sessions of the American-Diabetes-Association, Boston, MA USA, 5-9 June 2015. Alexandria, VA USA: American Diabetes Association.
-
Borg, D. J., Leung, S., Zhuang, A., Fotheringham, A., McCarthy, D., Di Trapani, J., Groop, P. -H., Knip, M. and Forbes, J. (2015). Delivery of recombinant human soluble receptor for advanced glycation end products delays autoimmune diabetes in the NOD mouse model. 51st Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Stockholm, Sweden, 14-18 September 2015. Heidelberg, Germany: Springer. doi: 10.1007/s00125-015-3687-4
Grants (Administered at UQ)
PhD and MPhil Supervision
Current Supervision
-
The receptor for advanced glycation end products and its role in Type 1 diabetes development
Doctor Philosophy — Associate Advisor
